WORLD WHO advises against Gilead's remdesivir for all hospitalized COVID-19 patients


WHO advises against Gilead's remdesivir for all hospitalized COVID-19 patients


21:26, November 20, 2020

The WHO has found no evidence that remdesivir helps hospitalized patients. (Photo: Reuters)

Gilead Sciences' drug remdesivir is not recommended for patients hospitalized with COVID-19, regardless how ill they are, as there is no evidence it improves survival or reduces the need for ventilation, a World Health Organization (WHO) panel said on Friday.

The panel "found a lack of evidence that remdesivir improved outcomes that matter to patients such as reduced mortality, need for mechanical ventilation, time to clinical improvement, and others."

The advice is another setback for the drug, which grabbed worldwide attention as a potentially effective treatment for COVID-19 in the summer after early trials showed some promise.

At the end of October, Gilead cut its 2020 revenue forecast, citing lower-than-expected demand and difficulty in predicting sales of remdesivir, which is also known as Veklury.


The antiviral is one of only two medicines currently authorized to treat COVID-19 patients across the world, but a large WHO-led study known as the Solidarity Trial showed last month that it had little or no effect on 28-day mortality or length of hospital stays for COVID-19 patients.

The medication was one of the drugs used to treat U.S. President Donald Trump's coronavirus infection, and had been shown in previous studies to have cut recovery time. It is authorized or approved for use as a COVID-19 treatment in more than 50 countries.

Gilead has questioned the Solidarity Trial's results. "Veklury is recognized as a standard of care for the treatment of hospitalized patients with COVID-19 in guidelines from numerous credible national organizations," the U.S. biopharmaceutical firm said in a statement.

"We are disappointed the WHO guidelines appear to ignore this evidence at a time when cases are dramatically increasing around the world and doctors are relying on Veklury as the first and only approved antiviral treatment for patients with COVID-19."

Solidarity Trial

Announced in March, the WHO's Solidarity Trial has investigated four different treatments – remdesivir, hydroxychloroquine, the combination of lopinavir/ritonavir, and lopinavir/ritonavir combined with interferon-beta. Trials of hydroxychloroquine were discontinued in July after no benefits were discovered.

The WHO's Guideline Development Group (GDG) panel said its recommendation on remdesivir was based on an evidence review that included data from four international randomized trials involving more than 7,000 patients hospitalised with COVID-19.

After reviewing the evidence, the panel said it concluded that remdesivir, which has to be given intravenously and is therefore costly and complex to administer, has no meaningful effect on death rates or other important outcomes for patients. "Especially given the costs and resource implications associated ... the panel felt the responsibility should be on demonstrating evidence of efficacy, which is not established by the currently available data," it added.

The latest WHO advice comes after one of the world's top bodies representing intensive care doctors said the antiviral should not be used for COVID-19 patients in critical care wards.

Peter Horby, a professor of emerging infectious diseases at the University of Oxford, said the advice should prompt, "a rethink about the place of remdesivir in COVID-19. Remdesivir is an expensive drug that must be given intravenously for five to 10 days, so this recommendation will save money and other healthcare resources," he said.

The WHO's recommendation, which is not binding, is part of its so-called "living guidelines" project, designed to offer ongoing guidance for doctors to help them make clinical decisions about patients in fast-moving situations such as the COVID-19 pandemic.

The panel added that it supported continued enrolment into clinical trials evaluating remdesivir in patients with COVID-19, which it said should "provide higher certainty of evidence for specific groups of patients."

The recommendation may raise further questions about whether the European Union will need the 500,000 courses of the antiviral, worth $1.2 billion, which it ordered last month.

Related Stories

Terms of Service & Privacy Policy

We have updated our privacy policy to comply with the latest laws and regulations. The updated policy explains the mechanism of how we collect and treat your personal data. You can learn more about the rights you have by reading our terms of service. Please read them carefully. By clicking AGREE, you indicate that you have read and agreed to our privacy policies

Agree and continue